June 12 – 17, 2022
Zika and dengue viruses are members of the Flavivirus genus that cause mild fever, rash and general body pain; but can cause severe reactions, as hemorrhages (dengue virus), congenital syndrome (Zika virus), or even death. Because of the structural similarity between these viruses, some antibodies generated after an infection can cross-react with different members of the flavivirus family. After a secondary infection, the cross-reactive antibodies can lead to more severe forms of the disease, through a mechanism named antibody-dependent enhancement of infection (ADE). Broadly neutralizing antibodies are antibodies that neutralize both, dengue and Zika viruses; and it has been demonstrated that they do not induce ADE. These antibodies are directed to a discontinuous quaternary epitope named the Envelope Dimer Epitope (EDE)1, located in the envelope (E) protein. To obtain the EDE, it is necessary to express the complete E protein, which contains other epitopes that induce ADE. This study aims to generate a peptide that emulates the EDE epitope structure (mimotope) in order to be used as a dual vaccine against dengue and Zika viruses; without causing ADE.
Please click Download on the upper right corner to see the full abstract.
Esmeralda Cuevas-Juárez, Arturo Liñan, Carolina Hernandez, Mykhailo Kopylov, Octavio T. Ramírez, and Laura A. Palomares, "Design of a vaccine against dengue and Zika viruses based on a mimotope of the envelope dimer epitope" in "Vaccine Technology VIII", Tarit Mukhopadhyay, Merck Research Laboratories, USA; Charles Lutsch, Sanofi Pasteur, France; Linda Hwee-Lin Lua, University of Queensland, Australia; Francesc Godia, Universitat Autònoma de Barcelona, Spain Eds, ECI Symposium Series, (2022). https://dc.engconfintl.org/vaccine_viii/102